Status:
UNKNOWN
Pharmacokinetics of Dexmedetomidine in Morbid Obesity
Lead Sponsor:
Guangzhou General Hospital of Guangzhou Military Command
Conditions:
Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Dexmedetomidine hydrochloride ,a relatively new drug in Chinais ,is a highly selective, potent a2-adrenoceptor agonist with significant analgesic, sedative and anxiolytic effects. The morbid obesity i...
Detailed Description
For the obese are sensitive to the disease such as hypertension, ischaemic heart disease and diabetes, the changes of the state may affect the pharmacokinetics of dexmedetomidine. Besides,the clearanc...
Eligibility Criteria
Inclusion
- Weight:28≦BMI≦45 and 18.5≦BMI≦24
- Written informed consent from the patient or the relatives of the participating patient.
Exclusion
- A previous history of intolerance to the study drug or related compounds and additives.
- Existing significant haematological, endocrine, metabolic or gastrointestinal disease.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2015
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01864187
Start Date
June 1 2013
End Date
July 1 2015
Last Update
March 12 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou Military Region General Hospital, Department of Anesthesiology
Guangzhou, Guangdong, China, 510010